Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 30, 2012Company Recognized for Outstanding Contributions to the Pharmaceutical Sciences
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has awarded its 2012...
-
May 17, 2012
Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48(th) Annual Meeting of the American Society...
-
May 10, 2012New Territories Include Canada, Mexico and Brazil
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, May 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement...
-
May 10, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, May 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and...
-
Apr 30, 2012
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Allen Waxman to the position of Senior Vice...
-
Apr 30, 2012H3 Biomedicine to employ Horizon's unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, and
-
Apr 19, 2012
Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku...
-
Apr 18, 2012
Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset...
-
Apr 16, 2012Clinical Study Seeks to Evaluate MORAb-004 plus best supportive care for Extending Progression-Free Survival of Patients with Chemorefractory Metastatic Colorectal Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of...
-
Mar 27, 2012Morphotek®, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian CancerClinical Study Seeks to Evaluate Farletuzumab in Combination with Standard of Care in First-Relapse Patients with Platinum-Sensitive Ovarian Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase 3...